ACHE and Alzheimer disease: In contrast to Li et al.’s liposomal approach [107], Misra et al. developed SLNs as an alternative nanocarrier system for the delivery of the acetylcholinesterase inhibitor GH, demonstrating another strategy for enhanced brain-targeted drug delivery in AD therapy.